Dr Obermayer-Pietsch has received travel grants and research support from Eli Lilly and Company. Dr Boonen has received research support from Eli Lilly and Company. Dr Fraser has received an unrestricted educational grant and honoraria from Eli Lilly and Company. Dr Hadji has received travel grants, speaker's honoraria, and consultancy fees from Eli Lilly and Company. Dr McCloskey has received research support and speaker's fees from Eli Lilly and Company. Drs Marin, Barker, and Nickelsen are full-time employees of Eli Lilly and Company. All other authors state that they have no conflicts of interest.
Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment†
Article first published online: 19 MAY 2008
Copyright © 2008 ASBMR
Journal of Bone and Mineral Research
Volume 23, Issue 10, pages 1591–1600, October 2008
How to Cite
Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., Hadji, P., Farrerons, J., Boonen, S., Audran, M., Barker, C., Anastasilakis, A. D., Fraser, W. D. and Nickelsen, T. (2008), Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment. J Bone Miner Res, 23: 1591–1600. doi: 10.1359/jbmr.080506
Preliminary data for this article were presented previously at the 28th Annual Meeting of the American Society for Bone and Mineral Research, September 15–19, 2006, Philadelphia, PA, USA, and at the 7th Annual Meeting of the European Congress on Clinical and Economic Aspects of Osteoporosis, March 28–31, 2007, Porto, Portugal.
- Issue published online: 4 DEC 2009
- Article first published online: 19 MAY 2008
- Manuscript Accepted: 12 MAY 2008
- Manuscript Revised: 30 APR 2008
- Manuscript Received: 5 MAR 2008
- antiresorptive therapy;
Previous antiresorptive (AR) treatment may influence the response to teriparatide. We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo. Patients were divided into three groups based on their prior AR treatment: treatment-naïve (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractures, persistent low BMD, and/or significant BMD loss while on therapy. Changes in BMD from baseline were analyzed using mixed model repeated measures. Lumbar spine BMD increased significantly from baseline at 6, 12, 18, and 24 mo in all three groups. The mean gain in spine BMD over 24 mo was greater in the treatment-naïve group (0.095 g/cm2; 13.1%) than in the AR pretreated (0.074 g/cm2; 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm2; 9.8%; p < 0.001) groups. The corresponding increases in total hip BMD were 3.8%, 2.3%, and 2.3%, respectively. Early decreases in hip BMD in the inadequate AR responder group were reversed by 18 mo of treatment. Increases in BMD between 18 and 24 mo were highly significant. Nausea (13.3%) and arthralgia (11.7%) were the most commonly reported adverse events. Asymptomatic hypercalcemia was reported in 5.0% of patients. Teriparatide treatment for 24 mo is associated with a significant increase in BMD in patients with and without previous AR use. Prior AR treatment modestly blunted the BMD response to teriparatide. Safety was consistent with current prescribing label information.